Publication: Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study
Loading...
Date
2011-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
OXFORD UNIV PRESS
Abstract
Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.
Description
Keywords
chemotherapy, combined modality treatment, non-Hodgkin's lymphoma, prognostic factors, radiotherapy, thyroid lymphoma, B-CELL LYMPHOMA, NON-HODGKINS-LYMPHOMA, MALIGNANT-LYMPHOMA, LOCALIZED INTERMEDIATE, ONCOLOGY-GROUP, GLAND, RADIOTHERAPY, CHEMOTHERAPY, THERAPY, CHOP